457 related articles for article (PubMed ID: 15866309)
1. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
[TBL] [Abstract][Full Text] [Related]
2. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
3. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
[TBL] [Abstract][Full Text] [Related]
4. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
5. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
[TBL] [Abstract][Full Text] [Related]
6. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
7. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
8. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study.
Zheng JP; Kang J; Huang SG; Chen P; Yao WZ; Yang L; Bai CX; Wang CZ; Wang C; Chen BY; Shi Y; Liu CT; Chen P; Li Q; Wang ZS; Huang YJ; Luo ZY; Chen FP; Yuan JZ; Yuan BT; Qian HP; Zhi RC; Zhong NS
Lancet; 2008 Jun; 371(9629):2013-8. PubMed ID: 18555912
[TBL] [Abstract][Full Text] [Related]
9. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
10. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
12. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
[TBL] [Abstract][Full Text] [Related]
13. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
16. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
[TBL] [Abstract][Full Text] [Related]
17. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
18. Quality control of spirometry: a lesson from the BRONCUS trial.
Pellegrino R; Decramer M; van Schayck CP; Dekhuijzen PN; Troosters T; van Herwaarden C; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Eur Respir J; 2005 Dec; 26(6):1104-9. PubMed ID: 16319343
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial.
Watz H; Barnacle H; Hartley BF; Chan R
Lancet Respir Med; 2014 Jan; 2(1):63-72. PubMed ID: 24461903
[TBL] [Abstract][Full Text] [Related]
20. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]